Login / Signup

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.

Sylvie BoyerMaël BaudoinMarie Libérée NishimweMelina SantosMaud LemoineGwenaëlle MaradanBabacar SyllaCharles KouanfackPatrizia CarrieriAbbas MouradNicolas RouveauRaoul MohMoussa SeydiAlain AttiaMaame Esi WoodeKarine Lacombe
Published in: BMC health services research (2022)
Generic sofosbuvir/daclatasvir is very cost-effective for treating chronic hepatitis C in sub-Saharan Africa. Large-scale use of generics and an increase in national and international funding for hepatitis C treatment must be priorities for the HCV elimination agenda.
Keyphrases
  • hepatitis c virus
  • combination therapy
  • human immunodeficiency virus
  • hepatitis c virus infection
  • liver fibrosis
  • smoking cessation